That was the patent release the other day I thought NB: 　...

That was the patent release the other day I thought NB:
　
Sydney, August 5, 2015 – US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN) today announced it had taken steps to augment the Company’s dominant intellectual property position on its anti-tropomyosin (ATM) technology platform with the lodgement of final specifications for two new patents covering its pioneering platform.
According to Group Vice President of Drug Discovery and Development, Dr Andrew Heaton, these patent specifications cover a wide range of novel ATM compounds, including the Company’s lead ATM drug candidate, Anisina. These patents add to the two previous ATM patents lodged in May 2015.
The active ingredient of Anisina is a small molecule targeting a protein component of the actin microfilament called tropomyosin (Tpm3.1), which researchers have shown to be essential for tumor cell survival in vitro. Additional in vitro studies have shown that inhibiting the function of Tpm3.1 with this family of novel ATM compounds causes tumor cell death across a broad range of cancer cell types. Pending the outcome of its manufacturing and toxicology programs, Anisina is expected to start Phase 1 clinical trials (first in human) in 2016.
"Over the past 18 months Novogen scientists have perfected the design and synthesis of extensive libraries of novel ATMs, using the Company’s VAL-ID (Versatile Approach to Library based Iterative Design) approach," Dr Heaton said.
"These final patent specifications represent two new families of ATMs and expand the structural diversity from the earlier ATM patents. The new patents focus on a range of new chemical libraries that are capable of enhanced specificity for the cancer-associated tropomyosin Tpm3.1, facilitating rapid lead identification."
"These additional patent specifications are a significant part of the Company’s R&D commitment to the technology platform and protect a critical asset."
"The patents enable Novogen to seamlessly commence a scale-up manufacturing process and to own that process outright. We have already commenced the large-scale manufacture of Anisina and have successfully produced multi-kilogram amounts to a standard suitable for advanced pre-clinical toxicity screening to allow us to conduct multiple clinical studies," Dr Heaton concluded.